Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)

Ingham, M., Allred, J. B., Chen, L., Das, B., Kochupurakkal, B., Gano, K., George, S., Attia, S., Burgess, M. A., Seetharam, M., Boikos, S. A., Bui, N., Chen, J. L., Close, J. L., Cote, G. M., Thaker, P. H., Ivy, S. P., Bose, S., D’Andrea, A., … Schwartz, G. K. (2023). Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). Journal of Clinical Oncology, 41(25), 4154–4163. https://doi.org/10.1200/jco.23.00402
Authors:
Matthew Ingham
Jacob B Allred
Li Chen
Biswasjit Das
Bose Kochupurakkal
Katherine Gano
Suzanne George
Steven Attia
Melissa A Burgess
Mahesh Seetharam
Sosipatros A Boikos
Nam Bui
James L Chen
Julia L Close
Gregory M Cote
Premal H Thaker
S Percy Ivy
Sminu Bose
Alan D'Andrea
Adrian Marino-Enriquez
Geoffrey I Shapiro
Gary K Schwartz
Affiliated Authors:
Matthew Ingham
Sminu Bose
Gary K Schwartz
Subjects:
Publication Type:
Article
Unique ID:
10.1200/jco.23.00402
PMID:
Publication Date:
Data Source:
PubMed

Record Created: